11 completed, 1 active not recruiting, 1 terminated. 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 11, Active not recruiting 1, Terminated 1 |
Follow linaclotide: new trials by email Literature Review of linaclotide trials Research Report on linaclotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide Linaclotide, Placebo - Functional Constipation | Phase 2 | Completed | AbbVie | 19 | 2023-04-27 | 2026-01-06 |
| Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer Linaclotide, Placebo - Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8 | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 150 | 2019-10-30 | 2026-10-08 |
| Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation Linaclotide, Placebo - Functional Constipation | Phase 2 | Completed | Allergan | 35 | 2019-10-14 | 2022-04-26 |
| A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) Placebo, LIN Dose A, LIN Dose B - Functional Constipation in Children Ages 6-17 Years | Phase 2 | Completed | Forest Laboratories | 173 | 2015-11-03 | 2019-06-19 |
| A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C - Irritable Bowel Syndrome With Constipation | Phase 2 | Terminated | Forest Laboratories | 101 | 2015-11-01 | 2020-12-28 |
| Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Linaclotide, Matching Placebo - Irritable Bowel Syndrome With Constipation | Phase 2 | Completed | Ironwood Pharmaceuticals, Inc. | 759 | 2015-10-22 | 2020-04-24 |
| A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation ASP0456, Placebo - Chronic Constipation | Phase 2 | Completed | Astellas Pharma Inc | 383 | 2015-04-13 | 2024-10-18 |
| Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo - Opioid-Induced Constipation | Phase 2 | Completed | Forest Laboratories | 254 | 2014-10-31 | 2019-04-08 |
| A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome linaclotide, placebo - Constipation-predominant Irritable Bowel Syndrome (IBS-C) | Phase 2 | Completed | Astellas Pharma Inc | 559 | 2012-08-10 | 2024-10-18 |
| Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Linaclotide Acetate, Matching placebo - Irritable Bowel Syndrome With Constipation | Phase 2 | Completed | Ironwood Pharmaceuticals, Inc. | 420 | 2007-04-01 | 2013-02-04 |
| Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation linaclotide acetate, Matching placebo - Chronic Constipation | Phase 2 | Completed | Ironwood Pharmaceuticals, Inc. | 310 | 2006-11-01 | 2013-03-05 |
| Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation MD-1100 Acetate - Constipation | Phase 2 | Completed | Ironwood Pharmaceuticals, Inc. | 40 | 2006-03-01 | 2009-03-24 |
| Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS MD-1100 Acetate - Irritable Bowel Syndrome | Phase 2 | Completed | Ironwood Pharmaceuticals, Inc. | 36 | 2006-01-01 | 2006-10-20 |
Constipation (3) · Irritable Bowel Syndrome (3) · Colorectal Neoplasms (1) · Opioid-Induced Constipation (1)
Ironwood Pharmaceuticals, Inc. (5) · Forest Laboratories (3) · Astellas Pharma Inc (2) · AbbVie (1) · Allergan (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (11) · Canada (3) · Japan (2) · Bulgaria (1) · Croatia (1) · Germany (1) · Hungary (1) · Serbia (1) · United Kingdom (1)
Anna Muslin (2) · Jeffrey M. Johnston, MD, FACP (1) · Michael Camilleri, MD (1) · Patricia D'Astoli, RN (1) · Paul Chamberlin, MD (1) · Scott Waldman, MD (1) · Taryn Weissman (1)
PMID 20045700, PMID 20801122, PMID 30084233, PMID 32310620, PMID 33065589, PMID 36324245, PMID 38504394, PMID 38962910
2019 (1)